In a recent publication, Wei Xu et al. proposed a novel approach for the diagnosis and monitoring of markers of myocardial infarction. The method is based on on-chip microarray analysis of serum biomarkers (e.g., cardiac troponin I) and when coupled with NIR-FE (NearInfraRed – fluorescent enhancement) showed a considerable increase in sensitivity and specificity over the chemiluminescent immunoassay approach, currently considered the gold standard in clinical diagnosis. Compartmentalization of the chip surface into isolated reaction wells was achieved by assembling the gold chip onto a ProPlate® Multi-Well Chambers. These chambers afford rapid device assembly and are ideally suited to conduct multiplex immunoassays. A sandwich assay was performed by printing capture antibodies against biomarkers of myocardial infarction on gold chips. Incubation with serum from patients and control individuals was followed by detection with specific antibodies. In conclusion, this study demonstrates that a plasmonic gold nano-island (pGold) chip assay can meet the stringent sensitivity and specificity requirements for point-of-care precision diagnostic requiring just a fraction of the volume of serum necessary for chemiluminescent immunoassay. Grace Bio-Labs offers solutions and technical expertise for the design and manufacturing of custom chambers for diagnostic applications.
Learn more here:
